Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARIOT: M6620 with Chemoradiotherapy in Oesophageal Cancer
NCT03641547Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Dec 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of berzosertib in esophageal carcinoma and solid tumor (3 arms), sponsored by University of Oxford. Primary endpoints: Dose Limiting Toxicities at 4 weeks and Recommended Phase 2 Dose at 24 weeks. Started Dec 2018; status: completed.
02
Drugs
berzosertib
03
Conditions
esophageal carcinomasolid tumor
Beyond the preview
Go deeper on NCT03641547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641547.